跳至主要内容
临床试验/ISRCTN69024008
ISRCTN69024008进行中(未招募)Unknown

A feasibility study to determine continuous glucose monitor-derived glucose variations when preventing therapeutic inertia in potentially over-treated older people with diabetes

University of Leicester0 个研究点目标入组 49 人开始时间: 2024年9月25日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
入组人数
49
主要终点
The percentage of participants achieving a composite of more than 50% time in range and less than 1% time below range, during the 12-week follow-up period. Measured via CGM continuously across the 12-week study.

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Aged 65 years or older
  • Confirmed diagnosis of type 2 diabetes
  • Currently on tablets for diabetes control, non-insulin injectable glucose-lowering therapies, insulin or any combination of these treatments
  • HbA1c less than 7.5% (58 mmol/mol) in the previous 12 months prior to the baseline search
  • Currently living in a care home setting (residential, nursing or mixed)
  • Participant is willing and able to give informed consent for participation OR if the participant lacks capacity, a consultee is willing to complete a consultee declaration form

排除标准

  • No confirmed diagnosis of type 2 diabetes
  • No diabetes medication issued in the 3 months before the database search for eligible participants
  • Aged 64 years old and younger
  • Last HbA1C reading >=7.5% (58 mmol/mol) in the previous 12 months prior to the baseline search
  • Participant has opted out of sharing their personal data as part of the national data opt-out policy
  • Receiving end-of-life care
  • Currently participating in a CTIMP study, or has participated in a CTIMP in the last 30 days
  • Is a temporary care home resident (i.e. less than 1 month of planned transitional/respite residential care)
  • Planning to travel away from the care home for >=2 weeks (on holiday, for example)

结局指标

主要结局

The percentage of participants achieving a composite of more than 50% time in range and less than 1% time below range, during the 12-week follow-up period. Measured via CGM continuously across the 12-week study.

次要结局

未报告次要终点

研究者

相似试验